Astec Lifesciences Key Ratios
NSE: ASTEC | BSE: 533138
₹572.55
As on 02-Sep-2026IST
Market cap
₹1,275 Cr
Revenue (TTM)
₹441 Cr
P/E Ratio
--
P/B Ratio
3.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -47.32 | -8.25 | 9.33 | -9.11 | -5.07 |
| EBIT | -349.23 | 47.80 | 49.66 | -224.98 | -186.05 |
| Net Profit | -141.30 | 43.34 | 49.64 | -321.07 | -200.84 |
| EPS | -141.28 | 49.77 | 53.90 | -314.62 | -199.05 |
| Book Value | -- | -- | 47.54 | -6.17 | 2.29 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -16.37 | -4.92 | -8.78 | -11.03 | -28.83 |
| Net Margin
| -20.95 | -9.14 | -14.93 | -17.84 | -34.82 |
| Return on equity
| -27.56 | -10.13 | -16.03 | -25.88 | -44.64 |
| Return on Capital
| -7.63 | 1.43 | -- | -5.71 | -12.62 |
| Return on Assets
| -9.39 | -2.84 | -7.30 | -8.84 | -14.47 |
| Debt to Equity (x)
| -- | -- | 0.13 | 1.15 | 2.36 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
-5.71
|
-12.62
|
-4.50
|
7.75
|
|
Peer Median
|
--
|
16.32
|
12.22
|
21.63
|
--
|
ROE
-16.03
Lower than Peers by 27.57
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-16.03
|
-25.88
|
-44.64
|
-11.90
|
6.28
|
|
Peer Median
|
11.54
|
12.46
|
9.23
|
18.08
|
--
|
ROA
-7.30
Lower than Peers by 14.59
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-7.30
|
-8.84
|
-14.47
|
-4.80
|
2.69
|
|
Peer Median
|
7.29
|
7.01
|
5.98
|
9.92
|
--
|
EBIT Margin
-8.78
Lower than Peers by 17.54
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-8.78
|
-11.03
|
-28.83
|
-9.20
|
6.78
|
|
Peer Median
|
8.75
|
10.36
|
9.68
|
7.64
|
--
|
Net Margin
-14.93
Lower than Peers by 21.84
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-14.93
|
-17.84
|
-34.82
|
-10.11
|
3.99
|
|
Peer Median
|
6.92
|
6.37
|
5.63
|
8.97
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
-8.02
|
-23.37
|
-2.32
|
9.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
9.33
Higher than Peers by 2.45
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
9.33
|
17.53
|
-16.78
|
-27.06
|
-7.15
|
|
Peer Median
|
6.88
|
8.30
|
7.71
|
-11.85
|
--
|
EBIT Growth
49.66
Higher than Peers by 36.12
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
49.66
|
55.02
|
-160.69
|
-198.98
|
-64.41
|
|
Peer Median
|
13.54
|
18.82
|
31.57
|
-36.92
|
--
|
Net Profit Growth
49.64
Higher than Peers by 35.34
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
49.64
|
39.96
|
-187.29
|
-283.21
|
-71.53
|
|
Peer Median
|
14.30
|
23.99
|
30.59
|
-41.41
|
--
|
EPS Growth
53.90
Higher than Peers by 42.74
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
53.90
|
46.76
|
-187.11
|
-283.54
|
-71.56
|
|
Peer Median
|
11.16
|
30.16
|
31.07
|
-42.07
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
66.42
|
-36.40
|
-11.96
|
5.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.13
Higher than Peers by 0.12
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.13
|
1.15
|
2.36
|
1.34
|
0.81
|
|
Peer Median
|
0.01
|
0.11
|
0.05
|
0.11
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
0.79
|
1.13
|
0.77
|
0.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.89
Lower than Peers by 1.06
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.89
|
0.89
|
0.93
|
1.00
|
0.95
|
|
Peer Median
|
1.94
|
1.79
|
2.07
|
1.63
|
--
|
Quick Ratio
0.61
Lower than Peers by 0.68
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.61
|
0.61
|
0.50
|
0.51
|
0.39
|
|
Peer Median
|
1.29
|
1.09
|
1.23
|
1.13
|
--
|
Interest Coverage
-1.14
Lower than Peers by 20.48
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-1.14
|
-1.35
|
-2.84
|
-1.45
|
2.69
|
|
Peer Median
|
19.34
|
17.49
|
12.22
|
12.03
|
--
|
Operating Efficiency
Debtors to sales
56.22
Higher than Peers by 24.71
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
56.22
|
55.28
|
38.67
|
36.89
|
24.66
|
|
Peer Median
|
31.51
|
27.44
|
30.54
|
25.72
|
--
|
Asset Turnover
0.48
Lower than Peers by 0.37
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
0.48
|
0.49
|
0.42
|
0.47
|
0.66
|
|
Peer Median
|
0.85
|
0.89
|
0.85
|
0.88
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
160.92
|
148.32
|
128.71
|
123.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
121.29
|
166.70
|
194.99
|
139.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
103.52
|
105.03
|
152.31
|
166.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
178.69
|
209.98
|
171.39
|
96.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-19.56
Lower than Peers by 43.09
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
-19.56
|
--
|
--
|
--
|
106.02
|
|
Peer Median
|
23.53
|
22.14
|
39.81
|
50.05
|
--
|
Price / Book Value
3.43
Higher than Peers by 0.75
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
3.43
|
3.08
|
5.64
|
5.65
|
6.47
|
|
Peer Median
|
2.67
|
2.46
|
4.60
|
3.48
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
--
|
--
|
--
|
--
|
0.11
|
|
Peer Median
|
0.27
|
0.26
|
0.20
|
0.55
|
--
|
EV/EBITDA
154.44
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
154.44
|
3,007.12
|
-30.96
|
-9,579.67
|
34.14
|
|
Peer Median
|
--
|
15.66
|
29.16
|
19.72
|
--
|
Market Cap
1,275
Lower than Peers by 2,220
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Astec Lifesciences
|
1,275
|
1,202
|
1,323
|
2,083
|
2,710
|
|
Peer Median
|
3,496
|
2,773
|
4,155
|
3,052
|
--
|